Adalimumab for Crohn's disease with intolerance or lost response to infliximab: A 3-year single-centre experience

Alimentary Pharmacology and Therapeutics

Volumn 29, Issue 4, 2009, Pages 416-423

  Oussalah, A ^a,b   Babouri, A ^a,b   Chevaux, J B ^a   Stancu, L ^a   Trouilloud, I ^a   Bensenane, M ^a,b   Boucekkine, T ^b   Bigard, M A ^a   Peyrin Biroulet, L ^a,c  

^a UNIVERSITY HOSPITAL OF NANCY   (France)

^b Benyoucef Benkhedda   (Algeria)

^c CHU NANCY BRABOIS   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; ADALIMUMAB; AZATHIOPRINE; BUDESONIDE; CERTOLIZUMAB PEGOL; INFLIXIMAB; MERCAPTOPURINE; MESALAZINE; METHOTREXATE; STEROID;

ACUTE GASTROENTERITIS; ADULT; AGED; ANGIONEUROTIC EDEMA; ARTHRALGIA; ARTICLE; COLON FISTULA; CONJUNCTIVITIS; CROHN DISEASE; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; FEVER; FLU LIKE SYNDROME; FURUNCULOSIS; GENITAL TRACT INFECTION; HAND INFECTION; HEADACHE; HEART PALPITATION; HERPES SIMPLEX KERATITIS; HUMAN; INFECTION; INJECTION SITE ERYTHEMA; LIVER ABSCESS; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; ONYCHOMYCOSIS; OTITIS; PHARYNGITIS; PRIORITY JOURNAL; PSORIASIS; RASH; RECURRENT INFECTION; SINUSITIS; SKIN TOXICITY; THRUSH; TOOTH ABSCESS; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; WHITLOW DISEASE;

ADOLESCENT; ADULT; AGED; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; CROHN DISEASE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE; FEMALE; HUMANS; MALE; MIDDLE AGED; REMISSION INDUCTION; TREATMENT OUTCOME;

EID: 58149302486     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2008.03902.x     Document Type: Article

References (20)

1. Peyrin-Biroulet L, Deltenre P, de Suray N, Branche J, Sandborn WJ, Colombel JF. Efficacy and safety of tumor necrosis factor antagonists in Crohn's disease: meta-analysis of placebo-controlled trials. Clin Gastroenterol Hepatol 2008 6 : 644 53.
2. Hanauer SB, Wagner CL, Bala M, et al. Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn's disease. Clin Gastroenterol Hepatol 2004 2 : 542 53.
3. Baert F, Noman M, Vermeire S, et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N Engl J Med 2003 348 : 601 8.
4. Farrell RJ, Alsahli M, Jeen YT, Falchuk KR, Peppercorn MA, Michetti P. Intravenous hydrocortisone premedication reduces antibodies to infliximab in Crohn's disease: a randomized controlled trial. Gastroenterology 2003 124 : 917 24.
5. Colombel JF, Sandborn WJ, Rutgeerts P, et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology 2007 132 : 52 65.
6. Hanauer SB, Sandborn WJ, Rutgeerts P, et al. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial. Gastroenterology 2006 130 : 323 33.
7. Sandborn WJ, Feagan BG, Stoinov S, et al. Certolizumab pegol for the treatment of Crohn's disease. N Engl J Med 2007 357 : 228 38.
8. Schreiber S, Khaliq-Kareemi M, Lawrance IC, et al. Maintenance therapy with certolizumab pegol for Crohn's disease. N Engl J Med 2007 357 : 239 50.
9. Sandborn WJ, Rutgeerts P, Enns R, et al. Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial. Ann Intern Med 2007 146 : 829 38.
10. Hinojosa J, Gomollon F, Garcia S, et al. Efficacy and safety of short-term adalimumab treatment in patients with active Crohn's disease who lost response or showed intolerance to infliximab: a prospective, open-label, multicentre trial. Aliment Pharmacol Ther 2007 25 : 409 18.
11. Youdim A, Vasiliauskas EA, Targan SR, et al. A pilot study of adalimumab in infliximab-allergic patients. Inflamm Bowel Dis 2004 10 : 333 8.
12. Sandborn WJ, Hanauer S, Loftus EV, et al. An open-label study of the human anti-TNF monoclonal antibody adalimumab in subjects with prior loss of response or intolerance to infliximab for Crohn's disease. Am J Gastroenterol 2004 99 : 1984 9.
13. Peyrin-Biroulet L, Laclotte C, Bigard MA. Adalimumab maintenance therapy for Crohn's disease with intolerance or lost response to infliximab: an open-label study. Aliment Pharmacol Ther 2007 25 : 675 80.
14. Seiderer J, Brand S, Dambacher J, et al. Adalimumab in patients with Crohn's disease - safety and efficacy in an open-label single centre study. Aliment Pharmacol Ther 2007 25 : 787 96.
15. Panaccione R, Sandborn WJ, D'Haens G, et al. Adalimumab maintains long-term remission in moderately to severely active Crohn's Disease after infliximab failure: 1-year follow-up of Gain trial. Gastroenterology 2008 134 (Suppl. 1 A133.
16. Ho GT, Smith L, Aitken S, et al. The use of adalimumab in the management of refractory Crohn's disease. Aliment Pharmacol Ther 2008 27 : 308 15.
17. Satsangi J, Silverberg MS, Vermeire S, Colombel JF. The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications. Gut 2006 55 : 749 53.
18. West RL, Zelinkova Z, Wolbink GJ, Kuipers EJ, Stokkers PC, van der Woude CJ. Immunogenicity negatively influences the outcome of adalimumab treatment in Crohn's disease. Aliment Pharmacol Ther 2008 28 : 1122 6.
19. Collamer AN, Guerrero KT, Henning JS, Battafarano DF. Psoriatic skin lesions induced by tumor necrosis factor antagonist therapy: a literature review and potential mechanisms of action. Arthritis Rheum 2008 59 : 996 1001.
20. Peyrin-Biroulet L, Desreumaux P, Sandborn WJ, Colombel JF. Crohn's disease: beyond antagonists of tumour necrosis factor. Lancet 2008 372 : 67 81.